Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
J Thorac Oncol., Sep;7(9):1361-8 (2012)
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Clin Lung Cancer., Sep;13(5):391-5 (2012)
Beyond bevacizumab: antiangiogenic agents.
Clin Lung Cancer., Sep;13(5):326-33 (2012)
Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.
Lung Cancer., Jun;76(3):410-5 (2012)
Phase III clinical trial development: a process of chutes and ladders.
Clin. Cancer Res., Nov;16(22):5381-9 (2010)
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Med. Oncol., Dec;28 Suppl 1:S152-61 (2011)
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
J. Clin. Oncol., Feb;28(6):949-54 (2010)
Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.
Oncologist., Nov;14(11):1106-15 (2009)
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501.
J. Clin. Oncol., Dec;27(35):6006-11 (2009)
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
J Thorac Oncol., Jun;4(6):722-7 (2009)
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Clin Lung Cancer., Mar;10 Suppl 1:S7-16 (2009)
Angiogenesis in the treatment of non-small cell lung cancer.
Proc Am Thorac Soc., Apr;6(2):206-17 (2009)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Clin Lung Cancer., Jan;10(1):20-7 (2009)
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Clin. Cancer Res., Mar;15(6):2158-65 (2009)
Steps and time to process clinical trials at the Cancer Therapy Evaluation Program.
J. Clin. Oncol., Apr;27(11):1761-6 (2009)
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
J. Clin. Oncol., Mar;27(9):1405-12 (2009)
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
J. Clin. Oncol., Nov;26(33):5407-15 (2008)
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
Invest New Drugs., Feb;27(1):75-81 (2009)
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naÃ¯ve advanced non-small cell lung cancer.
J Thorac Oncol., Jul;3(7):728-34 (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Clin. Cancer Res., Jul;14(14):4517-25 (2008)
Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Invest New Drugs., Aug;26(4):339-45 (2008)
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
J. Clin. Oncol., Mar;26(9):1472-8 (2008)
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Clin. Cancer Res., Mar;14(5):1407-12 (2008)
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
J. Clin. Oncol., Jan;26(1):60-5 (2008)
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).
Chest., Sep;132(3 Suppl):277S-289S (2007)
Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
Cancer Sci., Dec;98(12):1825-30 (2007)
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clin. Cancer Res., Aug;13(15 Pt 2):s4583-8 (2007)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
J. Clin. Oncol., Aug;25(23):3448-55 (2007)
The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
J Thorac Oncol., May;2(5):377-83 (2007)
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
J Thorac Oncol., Nov;1(9 Suppl):S32-6 (2006)
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.
J Thorac Oncol., Jun;1(5):441-6 (2006)
Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.
J. Clin. Oncol., Oct;24(28):4553-7 (2006)
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
J. Clin. Oncol., Oct;24(28):4545-52 (2006)
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Clin. Cancer Res., Jul;12(14 Pt 2):4365s-4371s (2006)
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Oncologist., Jun;11(6):655-65 (2006)
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Oncology (Williston Park, N.Y.)., May;20(6):626-8 (2006)
Nondermatologic adverse events associated with anti-EGFR therapy.
Oncology (Williston Park, N.Y.)., Apr;20(5 Suppl 2):35-40 (2006)
The safety of bevacizumab.
Expert Opin Drug Saf., Mar;5(2):289-301 (2006)
Targeting angiogenesis in lung cancer.
Semin. Oncol., Dec;32(6 Suppl 10):S16-22 (2005)
First-line treatment for advanced non-small-cell lung cancer.
Oncology (Williston Park, N.Y.)., Nov;19(13):1671-6; discussion 1678-80 (2005)
The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer.
Clin Adv Hematol Oncol., Dec;1(12):731-34 (2003)
State of the art in therapy for non-small cell lung cancer.
Cancer Invest., 23(5):427-42 (2005)
Epidermal growth factor receptor inhibitors in lung cancer therapy.
Semin Respir Crit Care Med., 25 Suppl 1:17-27 (2004)
Redefining bronchioloalveolar carcinoma.
Semin. Oncol., Jun;32(3):329-35 (2005)
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
J. Clin. Oncol., Jun;23(16):3752-9 (2005)
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Cancer Chemother. Pharmacol., Oct;56(4):329-36 (2005)
Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12.
Int. J. Radiat. Oncol. Biol. Phys., Jun;62(2):342-50 (2005)
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
Clin Lung Cancer., Dec;6 Suppl 1:S7-S19 (2004)
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Clin Lung Cancer., Dec;6 Suppl 1:S24-9 (2004)
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Clin. Cancer Res., Jun;10(12 Pt 2):4258s-4262s (2004)
Novel agents in the treatment of lung cancer: conference summary statement.
Clin. Cancer Res., Jun;10(12 Pt 2):4199s-4204s (2004)
COX-2 inhibition and lung cancer.
Semin. Oncol., Apr;31(2 Suppl 7):45-52 (2004)
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
Oncologist., 9 Suppl 1:19-26 (2004)
Epidermal growth factor receptor: a promising target in solid tumours.
Cancer Treat. Rev., Feb;30(1):1-17 (2004)
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.
Clin Lung Cancer., May;2 Suppl 2:S26-33 (2001)
Molecular targeted agents in non-small-cell lung cancer.
Clin Lung Cancer., Sep;5 Suppl 1:S22-8 (2003)
The importance of the eicosanoid pathway in lung cancer.
Lung Cancer., Aug;41 Suppl 1:S73-9 (2003)
Chemotherapy for small cell lung cancer.
Semin. Oncol., Feb;30(1):9-25 (2003)
Irinotecan in small-cell lung cancer: the US experience.
Oncology (Williston Park, N.Y.)., Jan;15(1 Suppl 1):11-2 (2001)
Chemotherapy in non-small cell lung cancer.
Invest New Drugs., May;18(2):157-86 (2000)
Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer.
Semin. Oncol., Feb;25(1 Suppl 2):38-41 (1998)
A phase II trial of paclitaxel in refractory germ cell tumors.
Cancer., Apr;82(7):1381-6 (1998)
Current management of small cell lung cancer.
Semin. Oncol., Aug;24(4):463-76 (1997)
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Clin. Cancer Res., Mar;3(3):409-17 (1997)
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
J. Clin. Oncol., May;13(5):1209-14 (1995)
Lung cancer: a review of current therapeutic modalities.
Lung., 170(5):249-65 (1992)